These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 6734032)

  • 1. Difference in erythrocyte catechol-O-methyltransferase activity between Orientals and Caucasians: difference in levodopa tolerance.
    Rivera-Calimlim L; Reilly DK
    Clin Pharmacol Ther; 1984 Jun; 35(6):804-9. PubMed ID: 6734032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low catechol-O-methyltransferase activity in a Saami population.
    Klemetsdal B; Straume B; Giverhaug T; Aarbakke J
    Eur J Clin Pharmacol; 1994; 46(3):231-5. PubMed ID: 8070503
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol-O-methyltransferase and Parkinson's disease.
    Tai CH; Wu RM
    Acta Med Okayama; 2002 Feb; 56(1):1-6. PubMed ID: 11873938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
    Sampaio TF; Dos Santos EUD; de Lima GDC; Dos Anjos RSG; da Silva RC; Asano AGC; Asano NMJ; Crovella S; de Souza PRE
    J Clin Pharmacol; 2018 Jul; 58(7):920-926. PubMed ID: 29578580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol-O-methyltransferase activity: a determinant of levodopa response.
    Reilly DK; Rivera-Calimlim L; Van Dyke D
    Clin Pharmacol Ther; 1980 Aug; 28(2):278-86. PubMed ID: 7398195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic variations in catechol-O-methyltransferase gene are associated with levodopa response variability in Chinese patients with Parkinson's disease.
    Zhao C; Wang Y; Zhang B; Yue Y; Zhang J
    Sci Rep; 2020 Jun; 10(1):9521. PubMed ID: 32533012
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.
    Heikkinen H; Nutt JG; LeWitt PA; Koller WC; Gordin A
    Clin Neuropharmacol; 2001; 24(3):150-7. PubMed ID: 11391126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ethnic differences in catechol O-methyltransferase pharmacogenetics: frequency of the codon 108/158 low activity allele is lower in Kenyan than Caucasian or South-west Asian individuals.
    McLeod HL; Syvänen AC; Githang'a J; Indalo A; Ismail D; Dewar K; Ulmanen I; Sludden J
    Pharmacogenetics; 1998 Jun; 8(3):195-9. PubMed ID: 9682265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers.
    Kaakkola S; Gordin A; Järvinen M; Wikberg T; Schultz E; Nissinen E; Pentikäinen PJ; Rita H
    Clin Neuropharmacol; 1990 Oct; 13(5):436-47. PubMed ID: 2272023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of monoamine oxidase B (MAOB) and catechol-O-methyltransferase (COMT) polymorphisms on levodopa therapy in patients with sporadic Parkinson's disease.
    Białecka M; Droździk M; Kłodowska-Duda G; Honczarenko K; Gawrońska-Szklarz B; Opala G; Stankiewicz J
    Acta Neurol Scand; 2004 Oct; 110(4):260-6. PubMed ID: 15355491
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia.
    Ivanova SA; Alifirova VM; Pozhidaev IV; Freidin MB; Zhukova IA; Osmanova DZ; Zhukova NG; Mironova YA; Tiguntsev VV; Fedorenko OY; Bokhan NA; Wilffert B; Loonen AJM
    J Pharm Pharm Sci; 2018; 21(1):340-346. PubMed ID: 30075828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of human erythrocyte and gastroduodenal catechol-O-methyltransferase activity by nitecapone.
    Schultz E; Tarpila S; Bäckström AC; Gordin A; Nissinen E; Pohto P
    Eur J Clin Pharmacol; 1991; 40(6):577-80. PubMed ID: 1884738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene polymorphisms and motor levodopa-induced complications in Parkinson's disease.
    Michałowska M; Chalimoniuk M; Jówko E; Przybylska I; Langfort J; Toczylowska B; Krygowska-Wajs A; Fiszer U
    Brain Behav; 2020 Mar; 10(3):e01537. PubMed ID: 32022467
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythrocytes catechol-o-methyl transferase activity is up-regulated after a 3-month treatment by entacapone in parkinsonian patients.
    Maltête D; Cottard AM; Mihout B; Costentin J
    Clin Neuropharmacol; 2011; 34(1):21-3. PubMed ID: 21164341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Introductory remarks: Catechol-O-methyltransferase inhibition--an innovative approach to enhance L-dopa therapy in Parkinson's disease with dual enzyme inhibition.
    Nissinen E
    Int Rev Neurobiol; 2010; 95():1-5. PubMed ID: 21095456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The catechol-O-methyltransferase and monoamine oxidase B polymorphisms and levodopa therapy in the Iranian patients with sporadic Parkinson's disease.
    Torkaman-Boutorabi A; Shahidi GA; Choopani S; Rezvani M; Pourkosary K; Golkar M; Zarrindast MR
    Acta Neurobiol Exp (Wars); 2012; 72(3):272-82. PubMed ID: 23093014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic polymorphism of catechol O-methyltransferase and pharmacokinetics of levodopa in healthy Chinese subjects.
    Lin CH; Wang CL; Huang PF; Liu YW; Ke M; Xu Y; Yu CX
    Methods Find Exp Clin Pharmacol; 2009; 31(6):389-95. PubMed ID: 19798454
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional COMT variant predicts response to high dose pyridoxine in Parkinson's disease.
    Tan EK; Cheah SY; Fook-Chong S; Yew K; Chandran VR; Lum SY; Yi Z
    Am J Med Genet B Neuropsychiatr Genet; 2005 Aug; 137B(1):1-4. PubMed ID: 15965967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.